ORKA (Oruka Therapeutics) Other Current Payables : $6.02 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics Other Current Payables?

Oruka Therapeutics's Other Current Payables for the quarter that ended in Dec. 2024 was $6.02 Mil.

Oruka Therapeutics's quarterly Other Current Payables stayed the same from . 20 ($0.00 Mil) to . 20 ($0.00 Mil) but then increased from . 20 ($0.00 Mil) to Dec. 2024 ($6.02 Mil).

Oruka Therapeutics's annual Other Current Payables stayed the same from . 20 ($0.00 Mil) to . 20 ($0.00 Mil) but then increased from . 20 ($0.00 Mil) to Dec. 2024 ($6.02 Mil).

Oruka Therapeutics Other Current Payables Historical Data

The historical data trend for Oruka Therapeutics's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics Other Current Payables Chart

Oruka Therapeutics Annual Data

Trend

Dec24

Other Current Payables

6.02

Oruka Therapeutics Semi-Annual Data
	Dec24
Other Current Payables	6.02

Oruka Therapeutics Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Oruka Therapeutics Other Current Payables Related Terms

Thank you for viewing the detailed overview of Oruka Therapeutics's Other Current Payables provided by GuruFocus.com. Please click on the following links to see related term pages.

Oruka Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (NAS:ORKA) » Definitions » Other Current Payables

Comparable Companies

Traded in Other Exchanges

HQ1:Germany

Address

855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025

Website

https://www.orukatx.com

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.